What is the clinical significance of a fasting C‑peptide of 0.55 ng/mL and what further evaluation or management is recommended?

Fasting C-peptide 0.55 ng/mL: Clinical Significance and Management

A fasting C-peptide of 0.55 ng/mL falls in a borderline zone that requires correlation with concurrent glucose levels and clinical context to determine if endogenous insulin secretion is appropriate or inappropriately suppressed.

Interpretation Framework

The clinical significance of this C-peptide value depends critically on the concurrent glucose level at the time of measurement:

If Glucose < 55 mg/dL (3.0 mmol/L):

This C-peptide level is inappropriately elevated and suggests endogenous hyperinsulinism (insulinoma or nesidioblastosis). The American consensus establishes that C-peptide should be < 0.6 ng/mL when glucose falls below 55 mg/dL 1. Your value of 0.55 ng/mL, while technically below this threshold, is borderline and warrants additional testing:

• Measure proinsulin: If > 5 pmol/L, this strongly supports hyperinsulinemic hypoglycemia 2, 1
• Measure beta-hydroxybutyrate (β-OHB): If < 2.7 mmol/L, this indicates suppressed ketogenesis from insulin excess 2
• Screen for oral hypoglycemic agents (sulfonylureas, meglitinides) to exclude factitious hypoglycemia 1

If Glucose 45-60 mg/dL (2.5-3.3 mmol/L):

This is a diagnostically challenging gray zone where C-peptide alone cannot distinguish normal from pathologic states 2. At these glucose levels:

• Proinsulin becomes the key discriminator:

  • 22 pmol/L = hyperinsulinemic hypoglycemia (100% specificity, 74% sensitivity) 2

  • < 5 pmol/L = appropriate response (normal finding) 2
  • 5-22 pmol/L = indeterminate, requires β-OHB and clinical correlation 2

• β-OHB > 2.7 mmol/L rules out insulin-mediated hypoglycemia with ~100% sensitivity and specificity 2

If Glucose > 60 mg/dL (3.3 mmol/L) - Diabetes Classification Context:

This C-peptide level suggests preserved beta-cell function, which has important implications for diabetes classification:

• < 0.2 nmol/L (< 0.6 ng/mL) suggests Type 1 diabetes or severe insulin deficiency 3
• Your value of 0.55 ng/mL is just below the 0.6 ng/mL threshold, placing you in a borderline category
• > 0.6 ng/mL (> 0.2 nmol/L) indicates Type 2 diabetes, MODY, or LADA 1, 3

For diabetes classification, this borderline value requires:

• Repeat testing when fasting glucose is ≤ 220 mg/dL (12.5 mmol/L) for accuracy 4
• Consider stimulated C-peptide testing (glucagon stimulation test) for definitive classification 5, 6
• Check diabetes autoantibodies (anti-GAD65, anti-IA2) to distinguish Type 1/LADA from Type 2/MODY 7

Critical Caveats

These thresholds are NOT valid in:

• Renal insufficiency - C-peptide clearance is impaired; use β-OHB and glucagon stimulation instead 2
• Hepatic insufficiency - thresholds not validated 2
• Post-pancreatectomy - altered insulin dynamics 2
• Within 2 weeks of diabetic ketoacidosis 3

Assay variability matters: Different C-peptide assays show significant variability and lack standardization 8. Verify your laboratory's reference ranges and methodology.

Recommended Next Steps

Immediate actions based on clinical scenario:

1. If evaluating hypoglycemia: Obtain simultaneous glucose, insulin, proinsulin, β-OHB, and screen for sulfonylureas during a documented hypoglycemic episode 1

2. If classifying diabetes type:

   • Measure diabetes autoantibodies
   • Consider glucagon-stimulated C-peptide if classification remains unclear 5
   • A stimulated C-peptide < 0.2 nmol/L confirms absolute insulin deficiency 6

3. If on insulin therapy: This level suggests some residual beta-cell function, which correlates with better glycemic control, lower insulin requirements, and reduced hypoglycemia risk 9

The 0.55 ng/mL value sits at a critical decision point where additional testing is essential rather than optional - isolated C-peptide interpretation without concurrent glucose and complementary markers will lead to diagnostic errors.